Association of hypertension and insulin resistance in individuals free of diabetes in the ELSA-Brasil cohort

Imagem de Miniatura
Arquivos
art_CASTRO_Association_of_hypertension_and_insulin_resistance_in_individuals_2023.PDF (926.57 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PORTFOLIO
Autores
CASTRO, Luisa
BRANT, Luisa
DINIZ, Maria de Fatima
CHOR, Dora
GRIEP, Rosane
BARRETO, Sandhi Maria
RIBEIRO, Antonio Luiz
Citação
SCIENTIFIC REPORTS, v.13, n.1, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Insulin resistance (IR) is defined as the subnormal response to insulin action on its target tissues. Studies suggest that IR may increase the risk of hypertension, but the results are inconsistent and it is not known whether such an effect is independent of overweight/obesity. We aimed to evaluate the association between IR and the incidence of prehypertension and hypertension in the Brazilian population and whether this association is independent of overweight/obesity. In 4717 participants of the Brazilian Longitudinal Study of Adult's Health (ELSA-Brasil), free of diabetes and cardiovascular disease at baseline (2008-2010), we investigated the incidence of prehypertension and hypertension after a mean follow-up of 3.8 +/- 0.5 years. Insulin resistance at baseline was assessed by the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) index, defined if above the 75th percentile. The risk of IR-associated prehypertension/hypertension was estimated by multinomial logistic regression after adjustment for confounding factors. Secondary analysis were stratified by body mass index. The mean (SD) age of participants was 48 (8) years, 67% were women. The 75th percentile of HOMA-IR at baseline was 2.85. The presence of IR increased the chance of developing prehypertension by 51% (95% CI 1.28-1.79) and hypertension by 150% (95% CI 1.48-4.23). In individuals with BMI < 25 kg/m(2), the presence of IR remained associated with the incidence of prehypertension (OR 1.41; 95% CI 1.01-1.98) and hypertension (OR 3.15; 95% CI 1.27-7.81). In conclusion, our results suggest that IR is a risk factor for hypertension, regardless of the presence of overweight or obesity.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/54589
Referências
  1. Aquino EML, 2013, REV SAUDE PUBL, V47, P10, DOI 10.1590/S0034-8910.2013047003953
  2. Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
  3. Ascaso JF, 2003, DIABETES CARE, V26, P3320, DOI 10.2337/diacare.26.12.3320
  4. Barreto SM, 2013, REV SAUDE PUBL, V47, P79, DOI 10.1590/S0034-8910.2013047003836
  5. Bensenor IM., 2013, REV SA DE P BLICA, V47, P37, DOI [DOI 10.1590/S0034-8910.2013047003780, 10.1590/S0034-8910.2013047003780]
  6. biblioteca.ibge, IBGE BIBL DET CAR EN
  7. Bonora E, 2000, DIABETES CARE, V23, P57, DOI 10.2337/diacare.23.1.57
  8. Chor D, 2013, REV SA DE P BLICA, V47, P27, DOI [10.1590/S0034-8910.2013047003835, DOI 10.1590/S0034-8910.2013047003835]
  9. da Silva AA, 2020, CAN J CARDIOL, V36, P671, DOI 10.1016/j.cjca.2020.02.066
  10. Fedeli LG, 2013, REV SAUDE PUBL, V47, P63, DOI 10.1590/S0034-8910.2013047003807
  11. Freeman A.M., 2020, STATPEARLS
  12. Geldsetzer P, 2019, LANCET, V394, P652, DOI 10.1016/S0140-6736(19)30955-9
  13. Hsia J, 2007, CIRCULATION, V115, P855, DOI 10.1161/CIRCULATIONAHA.106.656850
  14. Kanegae H, 2017, CURR HYPERTENS REP, V19, DOI 10.1007/s11906-017-0789-z
  15. Levin G, 2010, AM J EPIDEMIOL, V172, P1144, DOI 10.1093/aje/kwq266
  16. Lytsy P, 2014, J HYPERTENS, V32, P834, DOI 10.1097/HJH.0000000000000081
  17. Matsudo S., 2001, REV BRAS ATIVIDADE F, V6, P5, DOI [DOI 10.12820/RBAFS.V.6N2P5-18, 10.12820/rbafs.v.6n2p5-18]
  18. MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
  19. Mill JG, 2013, REV SAUDE PUBL, V47, P54, DOI 10.1590/S0034-8910.2013047003851
  20. Pinto MM, 2017, ARQ BRAS CARDIOL, V109, P416, DOI 10.5935/abc.20170146
  21. Quesada O, 2021, HYPERTENSION, V78, P716, DOI 10.1161/HYPERTENSIONAHA.120.16905
  22. Reaven Gerald, 2003, J Clin Hypertens (Greenwich), V5, P269, DOI 10.1111/j.1524-6175.2003.01764.x
  23. Rudvik A, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0521-y
  24. Saad MF, 2004, HYPERTENSION, V43, P1324, DOI 10.1161/01.HYP.0000128019.19363.f9
  25. Sabri S, 2005, Med J Malaysia, V60, P416
  26. SALOMAA V, 1995, CIRCULATION, V91, P1432, DOI 10.1161/01.CIR.91.5.1432
  27. Schmidt MI, 2015, INT J EPIDEMIOL, V44, P68, DOI 10.1093/ije/dyu027
  28. Sinaiko AR, 2006, HYPERTENSION, V48, P730, DOI 10.1161/01.HYP.0000237863.24000.50
  29. Sowers JR, 2004, AM J PHYSIOL-HEART C, V286, pH1597, DOI 10.1152/ajpheart.00026.2004
  30. Srivastava A, 2020, PREHYPERTENSION
  31. Stamatelopoulos K, 2019, GYNECOL ENDOCRINOL, V35, P1063, DOI 10.1080/09513590.2019.1630607
  32. Sung KC, 2011, AM J HYPERTENS, V24, P1041, DOI 10.1038/ajh.2011.89
  33. Tang Q, 2015, DRUG DISCOV THER, V9, P380, DOI 10.5582/ddt.2015.01207
  34. Tsimihodimos V, 2018, HYPERTENSION, V71, P422, DOI 10.1161/HYPERTENSIONAHA.117.10546
  35. Vasan RS, 2001, NEW ENGL J MED, V345, P1291, DOI 10.1056/NEJMoa003417
  36. Wang F, 2017, CLIN CHIM ACTA, V464, P57, DOI 10.1016/j.cca.2016.11.009

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - ODS/03